Medically reviewed on September 10, 2018
(al VI moe pan)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Entereg: 12 mg
Brand Names: U.S.
- Gastrointestinal Agent, Miscellaneous
- Opioid Antagonist, Peripherally-Acting
An opioid receptor antagonist which blocks opioid binding at the mu receptor; alvimopan has restricted ability to cross the blood-brain barrier at therapeutic doses. It selectively and competitively binds to the GI tract mu opioid receptors and antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion. Does not affect opioid analgesic effects or induce opioid withdrawal symptoms.
Vd: 20 to 40 L
Hydrolyzed to an amide hydrolysis compound (active metabolite) by gut microflora; further metabolism of active metabolite to glucuronide conjugates and other minor metabolites
Urine (~35% as unchanged drug and metabolites); feces (via biliary excretion)
Time to Peak
Plasma: Parent drug: ~2 hours; Metabolite: 36 hours
10 to 17 hours
Parent drug: 80%; metabolite: 94% (both primarily to albumin)
Special Populations: Renal Function Impairment
The half-life was comparable in patients with mild or moderate renal function impairment. There may be drug accumulation in patients with severe renal function impairment receiving multiple doses.
Special Populations: Hepatic Function Impairment
Drug exposure tended to be higher in patients with mild or moderate hepatic function impairment compared with healthy controls. There were no consistent effects on Cmax or half-life in patients with hepatic function impairment.
Use: Labeled Indications
Postoperative ileus: To accelerate the time to upper and lower GI recovery following surgeries including partial bowel resection with primary anastomosis
Use of opioids at therapeutic doses for more than 7 consecutive days immediately prior to alvimopan
Note: For short-term hospital use only.
Postoperative ileus: Oral: 12 mg 30 minutes to 5 hours prior to surgery, followed by 12 mg twice daily beginning the day after surgery until discharge for a maximum of 7 days (maximum total treatment: 15 doses [180 mg total])
Refer to adult dosing.
Dosing: Renal Impairment
Mild to severe impairment: No dosage adjustment necessary; use with caution.
ESRD: Use not recommended.
Dosing: Hepatic Impairment
Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution.
Severe impairment (Child-Pugh class C): Use not recommended.
Oral: For short-term hospital use only. Administer first dose 30 minutes to 5 hours prior to surgery. May be administered without regard to food.
High-fat meals may decrease the rate and extent of absorption
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased. Avoid combination
Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. Avoid combination
Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. Avoid combination
Opioid Analgesics: May enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Consider therapy modification
Note: Incidence reported limited to bowel resection patients only.
1% to 10%:
Endocrine & metabolic: Hypokalemia (10%)
Gastrointestinal: Dyspepsia (2% to 7%)
Genitourinary: Urinary retention (3%)
Hematologic and oncologic: Anemia (5%)
Neuromuscular & skeletal: Back pain (3%)
Frequency not defined:
Cardiovascular: Myocardial infarction
Concerns related to adverse effects:
• Cardiovascular effects: [US Boxed Warning]: A trend towards an increased incidence of MI was observed in alvimopan (low dose) treated patients compared to placebo in a 12-month study in patients treated with opioids for chronic pain. Other short-term studies have not observed this trend and a causal relationship has not been found. MI was generally observed more frequently in the initial 1 to 4 months of treatment.
• Anastomosis: Use not recommended in patients having gastric or pancreatic anastomosis.
• Complete bowel obstruction: Use not recommended in patients undergoing surgery for complete bowel obstruction.
• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment (Child-Pugh classes A and B); use not recommended with severe impairment (Child-Pugh class C).
• Renal impairment: Use with caution in patients with renal impairment; use not recommended in patients with ESRD.
Concurrent drug therapy issues:
• Opioids: Use with caution in patients recently exposed to opioids; may be more sensitive to gastrointestinal adverse effects (eg, abdominal pain, diarrhea, nausea and vomiting). Contraindicated in patients who have received therapeutic opioids for >7 consecutive days immediately prior to use.
• Japanese patients: Patients of Japanese descent should be monitored closely for gastrointestinal side effects (eg, abdominal pain, cramping, diarrhea) due to possibility of greater drug exposure; discontinue use if side effects occur.
• Appropriate use: [US Boxed Warning]: For short-term (≤15 doses) hospital use only. Only hospitals that have registered through the ENTEREG Access Support and Education (E.A.S.E.™) Program and met all requirements may use. It will not be dispensed to patients who have been discharged from the hospital.
GI adverse reactions (eg, abdominal pain, cramping, diarrhea) in patients receiving more than 3 doses of an opioid within the week prior to surgery, patients with mild to moderate hepatic impairment, with severe renal impairment, or in patients who are Japanese.
Pregnancy Risk Factor
Adverse events have not been observed in animal reproduction studies.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber angina, tachycardia, severe dizziness, passing out, severe headache, severe nausea, vomiting, abdominal pain, or abdominal cramps (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about alvimopan
- Alvimopan Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: peripheral opioid receptor antagonists
Other brands: Entereg